Sosei Group (JP:4565) has released an update.
Nxera Pharma, formerly known as Sosei Heptares, has reported strong progress in the second quarter of 2024, including the advancement of internal clinical trials and the development of partnered programs with significant milestones. The company is poised for commercialization of PIVLAZ® in South Korea by early 2025 and anticipates a positive decision on daridorexant in Japan. Financially, revenue saw a substantial increase, primarily from PIVLAZ® sales, with research and development, as well as general and administrative expenses also rising due to increased investment and organizational strengthening.
For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.
